Finding biomarkers to predict treatment benefits for a specific type of cancer
Identifying senescence and immune biomarkers predictive of benefit to combined CDK4 and checkpoint blockade inhibition in patients with dedifferentiated liposarcoma
This study is looking at a new treatment approach for people with a rare type of cancer called liposarcoma, by combining two medications to see if they can work better together, and it aims to find out which patients might benefit the most from this combination.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11086685 on NIH RePORTER |
What this research studies
This research focuses on patients with well-differentiated or dedifferentiated liposarcoma, a rare cancer that often does not respond to standard chemotherapy. The study aims to combine a CDK4/6 inhibitor, which has shown some effectiveness in stabilizing disease, with a PD1 checkpoint inhibitor to enhance treatment responses. Researchers will investigate the biological markers that can predict which patients are most likely to benefit from this combination therapy. By understanding the mechanisms of response and resistance, the goal is to improve patient outcomes and tailor treatments more effectively.
Who could benefit from this research
Good fit: Ideal candidates are patients diagnosed with locally advanced or metastatic well-differentiated or dedifferentiated liposarcoma.
Not a fit: Patients with other types of cancers or those who do not have the specific genetic markers associated with this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with a rare and challenging cancer.
How similar studies have performed: While the combination of CDK4/6 inhibitors and checkpoint inhibitors has shown promise in other cancers, this specific approach in dedifferentiated liposarcoma is relatively novel.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: D'angelo, Sandra P — Sloan-Kettering Inst Can Research
- Study coordinator: D'angelo, Sandra P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.